Predictors of growth and body composition in HIV-infected children beginning or changing antiretroviral therapy

HIV Medicine

Volumn 11, Issue 9, 2010, Pages 573-583

  Chantry, C J ^a   Cervia, J S ^b   Hughes, M D ^c   Alvero, C ^c   Hodge, J ^d   Borum, P ^e   Moye, J ^f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^d FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^e UNIVERSITY OF FLORIDA   (United States)

^f EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

Antiretroviral therapy; Body composition; CD4; Children; Fat redistribution; Growth; HIV; Viral load

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; ENFUVIRTIDE; FAT; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADOLESCENT; ANTHROPOMETRY; ARTICLE; BODY COMPOSITION; BODY FAT DISTRIBUTION; BODY MASS; CHILD; CONTROLLED STUDY; FEMALE; GROWTH; HEIGHT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMPEDANCE; LEAN BODY WEIGHT; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OBESITY; PARAMETER; PREDICTION; PREPUBERTY; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SKINFOLD THICKNESS; WEIGHT;

ADOLESCENT; ANTHROPOMETRY; ANTI-RETROVIRAL AGENTS; BODY COMPOSITION; BODY WEIGHTS AND MEASURES; CASE-CONTROL STUDIES; CHILD; CHILD DEVELOPMENT; CHILD, PRESCHOOL; ELECTRIC IMPEDANCE; ENERGY INTAKE; FEMALE; GROWTH DISORDERS; HIV INFECTIONS; HUMANS; INFANT; MALE; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 77956402797     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2010.00823.x     Document Type: Article

References (30)

1. McKinney RE, Robertson WR. Effect of human immunodeficiency virus infection on the growth of young children. J Pediatr 1993, 123:579-582.
2. Miller TL, Evans S, Orav EJ. Growth and body composition in children with human immunodeficiency virus-1 infection. Am J Clin Nutr 1993, 57:588-592.
3. Moye J, Rich KC, Kalish LA. Natural history of somatic growth in infants born to women infected by human immunodeficiency virus. J Pediatr 1996, 128:58-67.
4. Saavedra JM, Henderson RA, Perman JA. Longitudinal assessment of growth in children born to mothers with human immunodeficiency virus infection. Arch Pediatr Adolesc Med 1995, 149:497-502.
5. Lindegren ML, Steinberg S, Byers RH. Epidemiology of HIV/AIDS in children. Pediatr Clin N Am 2000, 47:1-20.
6. Chantry C, Byrd R, Englund J. Growth, survival and viral load in childhood HIV infection. Pediatr Infect Dis J 2003, 22:1033-1039.
7. Arpadi SM, Cuff PA, Kotler DP. Growth velocity, fat-free mass and energy intake are inversely related to viral load in HIV-infected children. J Nutr 2000, 130:2498-2502.
8. Pollack H, Glasberg H, Lee E. Impaired early growth of infants perinatally infected with human immunodeficiency virus: correlation with viral load. J Pediatr 1997, 130:915-922.
9. Miller TL, Easley KA, Zhang W. Maternal and infant factors associated with failure to thrive in children with vertically transmitted human immunodeficiency virus-1 infection: the prospective, P2C2 human immunodeficiency virus multicenter study. Pediatrics 2001, 108:1287-1296. for the Pediatric Pulmonary and Cardiovascular Complications of Vertically Transmitted HIV Infection (P2C2 HIV) Study Group, National Heart, Lung, and Blood Institute, Bethesda, MD.
10. Hilgartner MW, Donfield SM, Lynn HS. The effect of plasma human immunodeficiency virus RNA and CD4+T lymphocytes on growth measurements of hemophilic boys and adolescents. Pediatrics 2001, 107:e56. for the Hemophilia Growth and Development Study
11. Nachman SA, Lindsey JC, Pelton S. Growth in human immunodeficiency virus-infected children receiving ritonavir-containing antiretroviral therapy. Arch Pediatr Adolesc Med 2002, 156:497-503.
12. Buchacz K, Cervia JS, Lindsey JC. Impact of protease inhibitor-containing combination antiretroviral therapies on height and weight growth in HIV-infected children. Pediatr 2001, 108:e72. for the Pediatric AIDS Clinical Trials Group 219 Study Team.
13. Verweel G, van Rossum AM, Hartwig NG. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type-1-infected children is associated with a sustained effect on growth. Pediatrics 2002, 109:e25.
14. Van Rossum AC, Gaakeer MI, Verweel G. Endocrinologic and immunologic factors associated with recovery of growth in children and human immunodeficiency virus type 1 infection treated with protease inhibitors. Pediatr Infect Dis J 2003, 22:70-76.
15. Miller TL, Mawn BE, Orav EJ. The effect of protease inhibitor therapy on growth and body composition in human immunodeficiency virus type 1-infected children. Pediatrics 2001, 107:E77.
16. Fontana M, Zuin G, Plebani A. Body composition in HIV-infected children: relations with disease progression and survival. Am J Clin Nutr 1999, 69:1282-1286.
17. McDermott AY, Shevitz A, Knox T. Effect of highly active antiretroviral therapy on fat, lean, and bone mass in HIV-seropositive men and women. Am J Clin Nutr 2001, 74:679-686.
18. Brambilla P, Bricalli D, Sala N. Highly active antiretroviral-treated HIV-infected children show fat distribution changes even in absence of lipodystrophy. AIDS 2001, 15:2415-2422.
19. Verkauskiene R, Dollfus C, Levine M. Serum adiponectin and leptin concentrations in HIV-infected children with fat redistribution syndrome. Pediatr Res 2006, 60:225-230.
20. Arpadi SM, Cuff PA, Horlick M. Lipodystrophy in HIV-infected children is associated with high viral load and low CD4+-lymphocyte count and CD4+-lymphocyte percentage at baseline and use of protease inhibitors and stavudine. J Acquir Immune Defic Syndr 2001, 27:30-34.
21. Sánchez Torres AM, Munoz Muniz R, Madero R. Prevalence of fat redistribution and metabolic disorders in human immunodeficiency virus-infected children. Eur J Pediatr 2005, 164:271-276.
22. Melvin AJ, Lennon S, Mohan KM. Metabolic abnormalities in HIV type 1-infected children treated and not treated with protease inhibitors. AIDS Res Hum Retrovir 2001, 17:1117-1123.
23. Chantry CJ, Hughes MD, Alvero C. Lipid and glucose alterations in HIV-infected children beginning or changing antiretroviral therapy. Pediatrics 2008, 122:e129-e138.
24. Horlick M, Arpadi SM, Bethel J. Bioelectrical impedance analysis models for prediction of total body water and fat-free mass in healthy and HIV-infected children and adolescents. Am J Clin Nutr 2002, 76:991-999.
25. Kushner RF, Schoeller DA, Fjeld CR. Is the impedance index (ht2/R) significant in predicting total body water? Am J Clin Nutr 1992, 56:835-839.
26. Wells JC, Cole TJ. Adjustment of fat-free mass and fat mass for height in children aged 8 y. Int J Obes Relat Metab Disord 2002, 26:947-952. ALSPAC study team.
27. http://www.cdc.gov/nchs/about/major/nhanes/NHANES99-00.htm, http://www.cdc.gov/nchs/about/major/nhanes/NHANES01-02.htm, National Center for Health Statistics., National Health and Nutrition Examination Survey, 1999-2000 and 2001-2002 Public use data files. Center for Disease Control and Prevention Home Page. Available at, and, (accessed 15 March 2006)
28. Paul ME, Chantry CJ, Read JS. Morbidity and mortality during the first two years of life among uninfected children born to human immunodeficiency virus type 1-infected women: the women and infants transmission study. Pediatr Infect Dis J 2005, 24:46-56.
29. McDermott AY, Terrin N, Wanke C. CD4+cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study. Clin Infect Dis 2005, 41:1662-1670.
30. Moye J, Frederick M, Chantry C. 10-year follow-up of somatic growth in children born to women infected by human immunodeficiency virus. Chicago, IL, February 4-8, 2001 [Abstract no. 514].